header logo image


Page 1,554«..1020..1,5531,5541,5551,556..1,5601,570..»

Stem Cell Therapy for Cerebral Palsy – Holly Catalano

August 2nd, 2011 6:31 am

Holly is now able to crawl and sit up on her own just 7 weeks after her second treatment for cerebral palsy at the Stem Cell Institute in Panama City, Panama.

Go here to read the rest:
Stem Cell Therapy for Cerebral Palsy - Holly Catalano

Read More...

Poor Diet May Make COPD Worse, Study Finds

July 31st, 2011 4:06 pm

(HealthDay News) -- Certain vitamin deficiencies may lead to decreased lung function in people with chronic obstructive pulmonary disorder (COPD), which includes emphysema and chronic bronchitis, says a new study.

For the study, 20 COPD patients (13 women, seven men) completed a questionnaire to assess their dietary intake of vitamins A, C, D, E and selenium, all of which contain cell-protecting antioxidants. A diet low in antioxidants -- as compared to national dietary intake requirements -- was common among the patients.

The percentages of deficiencies were: 25 percent (selenium), 45 percent (vitamin C), 90 percent (vitamin E), 55 percent (vitamin A), and 70 percent (vitamin D).

The researchers then measured the maximum amount of air the patients could exhale with force. All the patients with a selenium-deficient diet had decreased lung function. Among patients deficient in vitamins C, A, and D, only men had decreased lung function. Read more...

Ayurtox for Body Detoxification

Read More...

Clinical trial costs

July 31st, 2011 4:06 pm
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com
Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

July 31st, 2011 4:06 pm
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

Poor Diet May Make COPD Worse, Study Finds

July 31st, 2011 4:03 pm

(HealthDay News) -- Certain vitamin deficiencies may lead to decreased lung function in people with chronic obstructive pulmonary disorder (COPD), which includes emphysema and chronic bronchitis, says a new study.

For the study, 20 COPD patients (13 women, seven men) completed a questionnaire to assess their dietary intake of vitamins A, C, D, E and selenium, all of which contain cell-protecting antioxidants. A diet low in antioxidants -- as compared to national dietary intake requirements -- was common among the patients.

The percentages of deficiencies were: 25 percent (selenium), 45 percent (vitamin C), 90 percent (vitamin E), 55 percent (vitamin A), and 70 percent (vitamin D).

The researchers then measured the maximum amount of air the patients could exhale with force. All the patients with a selenium-deficient diet had decreased lung function. Among patients deficient in vitamins C, A, and D, only men had decreased lung function. Read more...

Ayurtox for Body Detoxification

Read More...

Clinical trial costs

July 31st, 2011 4:03 pm
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com
Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

July 31st, 2011 4:03 pm
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

Stem Cell Therapy–Hillcrest Animal Hospital

July 31st, 2011 1:49 am

Hillcrest Animal Hospital, Bartlett, TN.....now doing in house stem cell therapy to relieve clinical signs of arthritis in dogs To learn more about stem cell therapy and how its helping animals across the United States, visit http://www.medivet-america.com

More:
Stem Cell Therapy--Hillcrest Animal Hospital

Read More...

Stem Cell Therapy – Knee Surgery Alternative

July 28th, 2011 6:21 pm

Helen shares her experiences with Dr. Matos and the Jacksonville Anti-Aging Institute. Helen suffered from severe leg and knee pain, had problems walking, and was unable to bend her knees up to her chest.

Read more from the original source:
Stem Cell Therapy - Knee Surgery Alternative

Read More...

The New World of Medicine: Stem Cell Therapy

July 26th, 2011 7:25 pm

In this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?

Original post:
The New World of Medicine: Stem Cell Therapy

Read More...

Adult Stem Cell Therapy Clinical Advances – Dr. Jorge Paz in San Diego, CA March 2011

July 26th, 2011 3:16 pm

Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined. Dr.

Original post:
Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011

Read More...

Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550

July 25th, 2011 11:18 pm

Amniotic Fluid Based Stem Cell Injections are being offered at Preferred Pain Center in Arizona. The injections offer an opportunity to harness the body's regenerative potential and exponentially increase it: 1) Anti-inflammation 2) Hyaluronic Acid 3) Stem Cells 4) Non-steroidal, non-embryonic treatment Pain relief plus potential regeneration of cartilage and soft tissues such as rotator cuff and ligaments. Now at Preferred Pain Center

Read the rest here:
Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550

Read More...

Meditation May Help Women Cope With Hot Flashes

July 24th, 2011 4:05 pm

(HealthDay News) -- An easy-to-learn meditation technique can help ease the hot flashes, night sweats and insomnia of menopause, a new study says.

The University of Massachusetts research showed that mindfulness training, based on a Buddhist meditation concept, reduced the distress associated with hot flashes and improved physical, psychosocial and sexual functioning.

"The findings are important because hormone replacement therapy, used to treat menopause symptoms in the past, has been associated with health risks," said study author James Carmody, an associate professor of medicine in the division of preventive and behavioral medicine.

About 40 percent of menopausal women suffer from hot flashes and night sweats, which undermine their quality of life, the researchers noted. But since hormone replacement therapy has been linked with an increased risk of heart disease, breast cancer and stroke, Carmody observed that "not only are women looking for alternative treatments, it is an NIH (National Institutes of Health) priority to find behavioral treatments Read more...

Cardiofy Heart Care Supplement

Read More...

New Report Details Uphill Battle to Solve the U.S.’s Pain Problem

July 24th, 2011 4:05 pm

Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Read More...

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

July 24th, 2011 4:05 pm
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Read More...

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

July 24th, 2011 4:05 pm
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
ras@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
# # #

Read More...

Meditation May Help Women Cope With Hot Flashes

July 24th, 2011 4:03 pm

(HealthDay News) -- An easy-to-learn meditation technique can help ease the hot flashes, night sweats and insomnia of menopause, a new study says.

The University of Massachusetts research showed that mindfulness training, based on a Buddhist meditation concept, reduced the distress associated with hot flashes and improved physical, psychosocial and sexual functioning.

"The findings are important because hormone replacement therapy, used to treat menopause symptoms in the past, has been associated with health risks," said study author James Carmody, an associate professor of medicine in the division of preventive and behavioral medicine.

About 40 percent of menopausal women suffer from hot flashes and night sweats, which undermine their quality of life, the researchers noted. But since hormone replacement therapy has been linked with an increased risk of heart disease, breast cancer and stroke, Carmody observed that "not only are women looking for alternative treatments, it is an NIH (National Institutes of Health) priority to find behavioral treatments Read more...

Cardiofy Heart Care Supplement

Read More...

New Report Details Uphill Battle to Solve the U.S.’s Pain Problem

July 24th, 2011 4:03 pm

Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Read More...

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

July 24th, 2011 4:02 pm
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Read More...

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

July 24th, 2011 4:02 pm
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
ras@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
# # #

Read More...

Page 1,554«..1020..1,5531,5541,5551,556..1,5601,570..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick